Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2–ACE2 Receptor Interactions
SARS-CoV-2, the causative agent of COVID-19, has caused more than 60 million cases worldwide with almost 1.5 million deaths as of November 2020. Repurposing existing drugs is the most rapid path to clinical intervention for emerging diseases.
Guardado en:
Autores principales: | Christopher J. Day, Benjamin Bailly, Patrice Guillon, Larissa Dirr, Freda E.-C. Jen, Belinda L. Spillings, Johnson Mak, Mark von Itzstein, Thomas Haselhorst, Michael P. Jennings |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
American Society for Microbiology
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/2b06afb56d02402cb0d88feb912f1af0 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The glycosylation in SARS-CoV-2 and its receptor ACE2
por: Yanqiu Gong, et al.
Publicado: (2021) -
The molecular basis for SARS-CoV-2 binding to dog ACE2
por: Zengyuan Zhang, et al.
Publicado: (2021) -
Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor
por: Jinsung Yang, et al.
Publicado: (2020) -
Human ACE2 receptor polymorphisms and altered susceptibility to SARS-CoV-2
por: Kushal Suryamohan, et al.
Publicado: (2021) -
Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry
por: Jiwan Ge, et al.
Publicado: (2021)